Available Doses of Estradiol Transdermal Patches
Estradiol transdermal patches are available in daily delivery doses ranging from 14 mcg/day to 100 mcg/day, with the most commonly available strengths being 25,50,75, and 100 mcg/day. 1
Standard Adult Dosing
The typical therapeutic range for hormone replacement therapy includes:
- 25 mcg/day - Low-dose formulation for symptom control 2
- 37.5 mcg/day - Low-dose formulation 2
- 50 mcg/day - Standard starting dose, most widely available globally 1, 3
- 75 mcg/day - Intermediate dose 4
- 100 mcg/day - Standard adult dose 1, 4
The FDA-approved dosing for oral estradiol ranges from 1-2 mg daily for most indications, with adjustments based on symptom control 5. For transdermal formulations, patches are typically changed twice weekly or weekly depending on the specific brand 1.
Ultra-Low Dose Formulations
Micro-dose patches delivering 14 mcg/day have demonstrated clinical efficacy for vasomotor symptoms, with a 41% responder rate (≥75% reduction in hot flushes) and approximately 95% reduction in moderate-to-severe hot flushes after 12 weeks 6. However, this ultra-low dose is available in only 3 countries globally 3.
Combined Estradiol-Progestin Patches
For women requiring endometrial protection, combined patches are available:
- 50 mcg estradiol + 10 mcg levonorgestrel daily (sequential regimen) 1
- 50 mcg estradiol + 7 mcg levonorgestrel daily (continuous regimen) 1
These combined formulations can be administered either sequentially (estradiol alone for 2 weeks, then combined for 2 weeks) or continuously without interruption 1.
Pubertal Induction Dosing
For adolescents requiring pubertal induction, a graduated approach is recommended 1:
- Initial dose (0-6 months): 1/8 to 1/4 of a standard patch
- 6-12 months: 1/4 of a patch weekly
- 12-18 months: 1/2 of a patch for 3-4 days, then 1/4 for remaining days
- 18-24 months: 1/2 of a patch weekly
- >24 months: 1 full patch weekly (adult dose)
Doses should be escalated at 6-month intervals over 24 months 1.
Clinical Considerations
The dose-response relationship is linear and proportional to patch strength, with serum estradiol levels of approximately 26,49, and 66 pg/mL achieved with 25,50, and 75 mcg/day patches respectively 4. The estradiol-to-estrone ratio improves to physiologic levels (0.51-1.09) with transdermal administration, compared to postmenopausal ratios of 0.15-0.21 4.
Global availability is limited for low-dose formulations, with 50 mcg patches available in 32 countries but 14 mcg and 25 mcg patches available in only 3 and 20 countries respectively 3. This creates practical challenges for initiating therapy at the lowest effective dose.
The transdermal route avoids first-pass hepatic metabolism, eliminating enhanced hepatic effects seen with oral administration while maintaining equivalent efficacy on non-hepatic markers 7. A 50 mcg patch produces effects comparable to 0.625 mg oral conjugated equine estrogen, while a 100 mcg patch is equivalent to 1.25 mg oral 7.